METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT CANCERS AND COMPOSITIONS THEREOF

(19)

(11)

EP 3 927 370 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	05.06.2024 Bulletin 2024/23

(45)	Mention of the grant of the patent:
	24.04.2024 Bulletin 2024/17

(21)	Application number: 20711461.2

(22)	Date of filing: 18.02.2020

(51)

International Patent Classification (IPC):

A61K 39/00^(2006.01)
A61P 37/04^(2006.01)
C12N 5/0783^(2010.01)

A61P 35/00^(2006.01)
C12N 5/0784^(2010.01)

(52)	Cooperative Patent Classification (CPC):
	A61P 35/00; A61P 37/04; C12N 5/0636; C12N 2501/2302; C12N 2501/515; C12N 5/0639; C12N 2502/1114; C12N 2502/1121; A61K 39/464401; A61K 39/4611; C12N 5/0638; A61K 39/464499; A61K 39/4632

(86)	International application number:
	PCT/US2020/018711

(87)	International publication number:
	WO 2020/172202 (27.08.2020 Gazette 2020/35)

(54)

METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT CANCERS AND COMPOSITIONS THEREOF

VERFAHREN ZUR HERSTELLUNG AUTOLOGER T-ZELLEN ZUR BEHANDLUNG VON KREBS UND ZUSAMMENSETZUNGEN DAVON

PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES T AUTOLOGUES UTILISÉS POUR TRAITER LES CANCERS, ET COMPOSITIONS ASSOCIÉES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

19.02.2019 US 201962807644 P
29.03.2019 US 201962826974 P
27.11.2019 US 201962941610 P
27.11.2019 US 201962941614 P

(43)	Date of publication of application:
	29.12.2021 Bulletin 2021/52

(60)	Divisional application:
	24162638.1

(73)	Proprietor: Turnstone Biologics Corp.
	La Jolla, CA 92037 (US)

(72)	Inventors:
	LANGER, Timothy J. New York, New York 10010 (US) CECCARELLI, Jacob New York, New York 10010 (US)

(74)	Representative: J A Kemp LLP
	80 Turnmill Street London EC1M 5QU London EC1M 5QU (GB)

(56)

References cited: :

WO-A1-2016/053339
US-A1- 2017 224 800

WO-A1-2018/183485

RAMI YOSSEF ET AL: "Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy", JCI INSIGHT, vol. 3, no. 19, 4 October 2018 (2018-10-04), XP055542887, DOI: 10.1172/jci.insight.122467
Y. LI ET AL: "MART-1-Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 1, 30 November 2009 (2009-11-30), pages 452-465, XP055210596, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901101

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).